7th Jun 2016 06:48
LONDON (Alliance News) - Oxford BioMedica PLC said Tuesday it has signed a new non-exclusive licence under its LentiVector platform technology patents for manufacturing and development services with Milan-based MolMed SpA.
The gene and cell therapy research and development company said that a previous patent agreement it had with MolMed has now expired.
"This agreement with MolMed is a further endorsement of our dominant patent estate and of our unique LentiVector platform technology for state-of-the-art bioprocessing and development services. Oxford BioMedica is already a partner for leading companies in the gene and cell therapy sector including Novartis, Sanofi, GSK and Immune Design," said Chief Executive Officer John Dawson in a statement.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica